DEC 01, 2021 8:00 AM PST

Researchers develop a novel drug that can combat diabetic tissue damage

WRITTEN BY: J. Bryce Ortiz

Diabetes is a common disease that occurs when high levels of blood sugar start to silently damage bodily tissue and organs. Approximately 34.2 million individuals in the United States are living with diabetes, and another 88 million are living with prediabetes which greatly increases the risk of developing diabetes. The disease often leads to debilitating tissue and organ damage. This typically manifests as broken bones that take a long time to heal, diabetes-induced blindness, kidney failure, and damage to other major organs such as the heart and bladder. While there is currently no cure for diabetes, researchers at New York University have recently developed a novel drug that they believe can help combat the tissue damage that accompanies the disease.

The researchers published their findings last week in the journal Science Translational Medicine. The research was based on past findings that a protein called RAGE (receptor for advanced glycation end products) can promote inflammation in numerous tissues throughout the body in individuals with diabetes. As such, the researchers designed a novel small-molecule drug that interact with RAGE to prevent inflammation. 

The researchers tested the drug, called RAGE229, in a mouse model of diabetes. The researchers used a test that triggered inflammation, wounds, and heart problems in mice. After inducing the diabetic-like complications in the mice, the researchers administered the drug. They found that in all three measures, RAGE229 was successful in significantly decreasing inflammation, improving wound healing time, and improving heart function in the diabetic-like mice. 

Lead researcher Ann Marie Schmidt, MD said in a statement, “Our results establish a molecular backbone of RAGE229 as the foundation for a new approach that targets intracellular RAGE actions to counter diabetic tissue damage.” The research team hopes that these findings will lead to the discovery of new drugs that will be capable of treating diabetic-induced tissue damage in humans.  

 

Sources:  CDCClinical and Experimental Pharmacology and PhysiologyWashington University in St. LouisScienceEurekalert

About the Author
  • Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
DEC 07, 2021
Microbiology
Gut Microbes Could Help Protect Us From Viral Infection, Including COVID-19
DEC 07, 2021
Gut Microbes Could Help Protect Us From Viral Infection, Including COVID-19
The human microbiome is closely connected to our immune system. Our bodies have to be able to keep the bacterial populat ...
DEC 12, 2021
Drug Discovery & Development
Cyagen: One-Stop Research Model & Gene Therapy Solutions
DEC 12, 2021
Cyagen: One-Stop Research Model & Gene Therapy Solutions
With gene therapy demonstrating an enormous potential to treat a wide range of diseases, Cyagen has added a range of gen ...
DEC 11, 2021
Health & Medicine
Third Dose of Pfizer-BioNTech Vaccine Could Reduce Effects of Omicron
DEC 11, 2021
Third Dose of Pfizer-BioNTech Vaccine Could Reduce Effects of Omicron
Many mainstream media sources are reporting on a new press release from Pfizer that suggests that a third dose of the Pf ...
DEC 30, 2021
Cancer
Integrative Oncology Prolongs Breast Cancer Survival
DEC 30, 2021
Integrative Oncology Prolongs Breast Cancer Survival
We often describe cancer according to where it originates, such as breast cancer, lung cancer, or pancreatic cancer.&nbs ...
JAN 11, 2022
Cannabis Sciences
Cannabis Varieties Used in Research Vary Significantly from Consumer Varieties
JAN 11, 2022
Cannabis Varieties Used in Research Vary Significantly from Consumer Varieties
Until just days ago, the University of Mississippi (UM) monopolized the cannabis research industry. Through a contract e ...
JAN 14, 2022
Drug Discovery & Development
Repurposing Drugs 101
JAN 14, 2022
Repurposing Drugs 101
Drug development is expensive. Taking into account costs of failed trials, the average drug costs $985 million to resear ...
Loading Comments...